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See Article, pages 1041–1048Sorafenib is the ﬁrst drug of proved clinical efﬁcacy on hepatocel-
lular carcinoma (HCC) as it provides a modest but signiﬁcant
increase in survival rate in patients with advanced HCC [1]. Ini-
tially developed as a Raf-1 kinase inhibitor, sorafenib also targets
other Raf kinase isoforms (wild-type B-Raf and oncogenic B-Raf
V600) and receptor tyrosine kinases such as vascular endothelial
growth factor receptors (VEGFR-2 and -3), platelet-derived
growth factor-b (PDGFR-b), Flt-3, and c-Kit. More recently, the
BCR/ABL kinase has been also identiﬁed as a sorafenib target
[2]. The broad spectrum of actions of sorafenib against kinases
involved in neovascularisation and tumor progression is sup-
posed to contribute to its potent activity towards tumor angio-
genesis and tumor growth in a variety of tumors including HCC
[3]. Accordingly, in vitro and in vivo studies have shown that
sorafenib promotes antiproliferative and proapoptotic effects in
tumor cells as well as in endothelial cells. However, it appears
that the molecular mechanisms underlying the direct effects of
sorafenib in these cells are not completely understood and they
probably involve additional pathways.
Consistent with its inhibitory activity towards Raf kinases,
sorafenib impairs the ERK signaling pathway in diverse tumor
cell types and this effect has been linked to the antiproliferative
action of sorafenib. However, there are also substantial data
showing that sorafenib antiproliferative activity does not fully
correlate with the inhibition of ERK phosphorylation and with
the downregulation of cyclin D1. This discrepancy was observed
in different tumor cell types including HCC cells [4–6]. Regarding
apoptosis, sorafenib treatment is frequently associated with the
downregulation of the anti-apoptotic Bcl-2 family member Mcl-
1 and survivin. Several studies have shown that Mcl-1 and survi-
vin downregulation occurs through a MEK/ERK-independent
mechanism [7–9]. As compelling data continue to accumulate,
it now appears that STAT3 inhibition may be responsible for
the ERK-independent effects of sorafenib.
STAT3 (for Signal Transducer and Activator of Transcription 3)
represents a key transducer in signaling pathways involved in theJournal of Hepatology 20
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chronic liver diseases and human HCC development [10]. STAT3
is inactive in non-stimulated cells but is rapidly activated by var-
ious cytokines and growth factors such as interleukin-6 (IL-6),
epidermal growth factor (EGF) family members or hepatocyte
growth factor and acts as a nuclear transcription factor. STAT3
activation requires Tyr705 phosphorylation by different kinases
such as Janus kinases, Src, EGFR, or MEK kinase 1, which results
in STAT3 dimerization, nuclear translocation, DNA binding, and
gene transcription. STAT3-stimulated genes promote angiogene-
sis, proliferation, and survival and include genes coding for cyclin
D1,Mcl-1 and survivin. STAT3 activation also turns on strong neg-
ative feedback loops involving tyrosine phosphatases (SHP1 and
SHP2) and suppressors of cytokine signaling (SOCS). By reducing
the levels of phospho-STAT3, phosphatases block STAT3 dimer-
ization and transcriptional activity, thus insuring that STAT3 acti-
vation is a transient event in normal cells.
STAT3 is constitutively activated (i.e. phosphorylated) in most
cancers, including 60% of HCC as a result of inﬂammation, oxida-
tive stress, growth factor stimulation, epigenetic silencing of
SOCS, and low expression levels of phosphatases [10]. IL-6 and
STAT3 are required for tumorigenesis in the mouse liver. IL-6-
or STAT3-deﬁcient mice exhibit a marked reduction of diethylni-
trosamine (DEN)-induced liver carcinogenesis in comparison to
wild-type mice [11,12]. SHP2 ablation enhances DEN-induced
HCC development which is abolished by concurrent deletion of
SHP2 and STAT3 in hepatocytes [13].
It has been recently observed that sorafenib inhibits Tyr705
STAT3phosphorylation in a varietyof tumorcells includingmedul-
loblastoma [5], cholangiocarcinoma [14], and HCC [15]. The
inhibition of STAT3 signaling and the subsequent downregulation
of Mcl-1 play a prominent role in sorafenib-induction of apoptosis
in these cells. The mechanism whereby sorafenib prevents STAT3
activation has been addressed by Gores’s laboratory in cholangio-
carcinoma cells [14]. Their study showed that sorafenib promotes
Tyr705 STAT3dephosphorylationby stimulatingphosphatase SHP2
activity since theknockdownof SHP2using siRNAtechnologyabro-
gated sorafenib-stimulated Tyr705 STAT3 dephosphorylation. As
the Raf kinase inhibitor ZM336372 also resulted in Tyr705 STAT3
dephosphorylation, this result led the authors to conclude that
sorafenib promotes Tyr705 STAT3 dephosphorylation by inhibiting
Raf-1 kinase activity in cholangiocarcinoma.11 vol. 55 j 957–959
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In the present issue of the Journal of Hepatology [16], the study
by Tai and colleagues provides new insights regarding the mech-
anism whereby sorafenib affects STAT3 activity in HCC cells. The
authors have developed a series of sorafenib analogs whose char-
acteristics are reported elsewhere [17]. Among them, SC-1 is a
sorafenib derivative lacking inhibitory activity towards Raf-1
and VEGFR-2 kinases. Interestingly, SC-1 was as potent as sorafe-
nib in the inhibition of cell viability and the induction of apopto-
sis in vitro in human HCC cell lines and endothelial cells.
Antiproliferative and proapoptotic effects of SC-1 and sorafenib
were both associated with a marked decrease of STAT3 phosphor-
ylation and transcriptional activity and the downregulation of
Mcl-1, cyclin D1, and survivin. The antitumoral effect of SC-1
was conﬁrmed in vivo by using a subcutaneous xenograft model
of HCC into nude mice and was comparable to that obtained with
sorafenib. Based on these results, these authors propose that
sorafenib mediates cell growth arrest and apoptosis through a
Raf-1- and VEGFR2-independent mechanism in HCC and endo-IL-6R
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Fig. 1. Role of STAT3 inibition in sorafenib-mediated antitumoral effects. In cancer c
constitutively active non-receptor tyrosine kinases (such as Src and ABL). After tyrosine
nucleus, where they directly regulate the expression of genes involved in proliferation, s
inhibitor of STAT3 phosphorylation which plays a major role in sorafenib-mediated antitu
SHP1 and is independent of Raf-1 and VEGF-R2 inhibition since it is mimicked by SC-1,
958 Journal of Hepatology 201thelial cells and that STAT3 dephosphorylation is a major signal-
ing event involved in these effects. Further support for this
contention was obtained with experiments showing that Raf-1
silencing with small interference RNA had no impact on SC-1
and sorafenib repression of Tyr705 STAT3 phosphorylation.
Rather, the authors report that SC-1 and sorafenib potently stim-
ulated in vitro and in vivo the activity of the phosphatase SHP1,
probably through direct binding to the phosphatase. SHP1 activa-
tion was required for SC-1 and sorafenib induction of apoptosis
and STAT3 dephosphorylation.
This study therefore highlights the major contribution of
STAT3 in sorafenib-mediated antitumoral effects on HCC cells
and demonstrates that Raf-1 and VEGFR2, the main classical tar-
gets of this drug, seem paradoxically to play a negligible role
(Fig. 1). In addition, this study reinforces the necessity of testing
inactive analogs -when available- to precise the main (and true)
molecular mechanisms of antitumoral activity of new pharmaco-
logical compounds (as another example, LY303511, the ‘‘inactiveVEGFREGFR
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ells, STAT3 can be activated by overactive receptor (such as IL-6R and EGFR) and
phosphorylation on residue 705, STAT3 molecules dimerize and translocate to the
urvival, and angiogenesis. In HCC and endothelial cells, sorafenib is a very potent
moral effects. This effect involves the direct activation of the tyrosine phosphatase
a sorafenib analog devoided of inhibitory activity towards these two kinases.
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analog’’ of the widely used phosphatidylinositide-3-kinase inhib-
itor LY294002, presents an antitumoral activity by itself [18]).
This paper raises also important questions. It is still unclear
whether SC-1 has no kinase inhibition activity or if it still
maintains some inhibitory effects on other sorafenib targets such
as Raf isoforms and PDGFR-b. The present study was largely con-
ducted in vitro and the subcutaneous xenograft model has some
limitations regarding the contribution of the immune system
and the tumor microenvironment to HCC development. It is not
excluded that SC-1 and sorafenib may present some different
effects in vivo, in particular on tumor angiogenesis.
This paper clearly reinforces the interest of STAT3 as a new
potential therapeutic approach for HCC. Indeed, studies using
STAT3 inhibitors show that STAT3 is not required for the survival
of differentiated cells and may be therefore targeted in human
cancers. Different STAT3 inhibitors have been designated to
directly target STAT3 mainly by inhibiting its dimerization, DNA
binding, or nuclear entry [19,20]. However, of these inhibitors,
a few show good activity in terms of inhibition of STAT3 biolog-
ical functions and associated antitumor effects in murine models.
The need remains therefore high for suitable and effective STAT3
inhibitors for clinical application in cancer. The ultimate and
obvious question is how well (and how long) patients will
respond to speciﬁc STAT3 inhibitors.Conﬂict of interest
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